An interventional study of Return to work coordinator + PRATICAdr 2.0 and Return to work coordinator only in Common Mental Disorder, sponsored by Université du Québec a Montréal. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Université du Québec a Montréal · Not applicable, Interventional, and Supportive care
This study aims to assess the effectiveness of PRATICAdr 2.0, a web application facilitated by a Return-to-Work Coordinator (RTW-C), with a focus on reducing sick leave duration and preventing relapse in individuals with CMDs. PRATICAdr 2.0 designed to enhance collaboration among Return-to-Work (RTW) stakeholders and provide systematic support throughout the RTW process, is evaluated in a randomized control trial (RCT). As part of the RCT, a total of 80 sick leave employees from 4 large public health organizations (n=80, 40 from the experimental group and 40 from the control group) will be recruited. The control group receives usual services offered by a RTW-C to sick leave employees, while the experimental group receives RTW-C services plus the use of PRATICAdr 2.0.
Common mental disorders (CMDs) are highly prevalent in workplace settings, and have become a significant public health challenge. This study aims to assess the effectiveness of PRATICAdr 2.0, a web application facilitated by a Return-to-Work Coordinator (RTW-C), with a focus on reducing sick leave duration and preventing relapse in individuals with CMDs. PRATICAdr 2.0 designed to enhance collaboration among Return-to-Work (RTW) stakeholders and provide systematic support throughout the RTW process, is evaluated in a randomized control trial (RCT). As part of the RCT, a total of 80 sick leave employees from 4 large public health organizations (n=80, 40 from the experimental group and 40 from the control group) will be recruited. The control group receives usual services offered by a RTW-C to sick leave employees, while the experimental group receives RTW-C services plus the use of PRATICAdr 2.0. Participants will be randomly assigned to either the PRATICAdr 2.0 experimental group or the control group using computerized stratified randomization based on age, site, and sex (sealed envelope method). Participants will complete a series of online questionnaires at several following time points. Survival analyses were used to compare sick leave durations and relapses between the experimental group (PRATICAdr with RTW-C), and control groups (RTW-C only). Mixed linear models were used to observe changes in clinical symptoms over time, especially for the experimental group.
Université du Québec a Montréal is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process. In this arm, the RTW-C uses PRATICAdr 2.0, a web application including key features (e.g., Facilitation of collaboration among multiple RTW stakeholders across healthcare, enterprise, and insurance sectors; Integration of each stakeholder's action into the sick leave employee's RTW process; sequential process aligned with the three phases of the RTW, inclusion of tools).
Behavioral: Return to work coordinator + PRATICAdr 2.0
The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process. In this arm, the RTW-C does not use PRATICAdr 2.0.
Behavioral: Return to work coordinator only
The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).
The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual
Sick leave duration
The number of days during the sick leave
Time frame: through study completion, an average of 2 years
Relapses
Number of relapses after returning to work
Time frame: through study completion, an average of 2 years
Depressive symptoms
Patient Health Questionnaire for depression (PHQ-9; Kroenke et al., 2001)
Time frame: through study completion, an average of 2 years
Anxiety symptoms
Generalized Anxiety Disorder Scale (GAD-7; Spitzer et al., 2006)
Time frame: through study completion, an average of 2 years
Return to Work Obstacles and Self-Efficacy
Return to Work Obstacles and Self-Efficacy Scale (ROSES ; Corbière et al., 2017 )
Time frame: through study completion, an average of 2 years
Social functioning
WHODAS
Time frame: through study completion, an average of 2 years
Working alliance
Working Alliance Inventory (Horvath \& Greenberg, 1989; Corbière et al., 2006)
Time frame: through study completion, an average of 2 years
Work accommodations
Work Accommodation and Natural Support Scale (WANSS; Corbière et al., 2014)
Time frame: through study completion, an average of 2 years
Work recognition
Recognition by stakeholders of returning to work following a common mental disorder (RECONNECT, Corbière, Larivière, Charette-Dussault, 2021)
Time frame: through study completion, an average of 2 years
Ran from May 2024 to primary completion in Apr 2026, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université du Québec a Montréal